Amendments to the Claims

1. (Currently Amended) A compound of the following formula:



(I)

or a pharmaceutically acceptable salt or N-oxide thereof;

wherein

A is aryl or ~~heteroaryl~~ furanyl;

~~each of~~ R^2 and R^3 ~~is independently~~ are hydrogen~~, alkyl, cycloalkyl, cycloalkenyl, aryl, or aralkyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, or heteroaralkyl~~;

~~each of~~ X^1 is alkynylene;

[[,]] X^2, and X^3 ~~is independently~~ are a bond~~, C_{1-6} alkylene, C_{2-6} alkenylene, or C_{2-6} alkynylene; each of said C_{1-6} alkylene, C_{2-6} alkenylene, and C_{2-6} alkynylene being optionally substituted alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, cyano, guanadino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, heterocyloalkylalkyl, aryl, aryloxy, arylsulfanyl, aroyl, aralkyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, heteroaroyl, or heteroaralkyl~~;

L is ~~a bond or~~ a linker of the following formula: ~~selected from the group consisting of:~~















,



,



~~, and~~



;

wherein:

~~each of~~ R' ~~and R", independently,~~ is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, sulfoxy, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, or heteroaroyl; provided that two adjacent R' groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety;

~~X^a is $C(R^2)(R^3)$, S, SO, or SO_2;~~

~~X^b is $C(R^2)(R^3)$, NR^2, O, S, SO, or SO_2;~~

each of p, q, and m, independently, is 0-3;

~~each of m1 and m2, independently, is 0-2;~~

~~each of r and r1, independently, is 1 or 2;~~

~~each of p1, p2, q1, and q2, independently, is 0-2;~~

~~r2 is 0 or 1;~~

~~n1 is 0-6; and~~

~~n2 is 2-6;~~

Y is ~~$-NR^a-$, $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-CO-$, $-CO_2-$, $-O-CO-$, $-CO-NR^a-$, $-NR^a-CO-$, $-SO_2-NR^a-$, $-NR^a-SO_2-$, $-NR^a-CO-NR^b-$, $-NR^a-CO-O-$, $-O-CO-NR^a-$, or~~ a bond; ~~where each of R^a and R^b is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkenylalkyl, heterocycloalkenylalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;~~ and

R^1 is hydrogen~~, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, or heterocyclyl; each of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl being optionally substituted alkyl, alkenyl, alkynyl, alkoxy, formyl, acyl, halo, hydroxy, amino, nitro, cyano, guanadino, amidino, oxo, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, heterocyloalkylalkyl, aryl, aryloxy, arylsulfanyl, aroyl, aralkyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, heteroaroyl, or heteroaralkyl; provided that when each of X^1, L, X^2, Y, and X^3 is a bond, R^1 is not hydrogen~~.

2-34. (Canceled)

35. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

36-56. (Canceled)

57. (New) The following compound:
2-Furan-2-yl-6-[1-(2,4,6-trifluoro-benzylamino)-cyclohexylethynyl]-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamine.

58. (New) The following compound:
1-(8-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrazin-6-ylethynyl)-cyclobutanol.

59. (New) The following compound:
1-(8-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrazin-6-ylethynyl)-cyclopentanol.

60. (New) The following compound:
1-[8-Amino-2-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-ylethynyl]-cyclopentanol.

61. (New) The following compound:
1-(8-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrazin-6-ylethynyl)-cyclohexanol.

62. (New) The following compound:
2-(8-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrazin-6-ylethynyl)-indan-2-ol.

63. (New) The following compound:
1-(8-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrazin-6-ylethynyl)-2,2,6-trimethyl-cyclohexanol.

64. (New) The following compound:
6-(3-Cyclohexyl-prop-1-ynyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamine.

65. (New) The following compound:
6-(3-Cyclopentyl-prop-1-ynyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamine.

66. (New) The following compound:
6-(1-Amino-cyclohexylethynyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrazin-8-ylamine.

67. (New) A pharmaceutical composition comprising a compound of anyone of claims 57-66 and a pharmaceutically acceptable carrier.